A Study to Evaluate ABP 938 & Aflibercept (Eylea®) in Participants With

Clinical Trial Summary

The primary objective of this study is to is to assess the ability of retina specialists to successfully administer, via an intravitreal (IVT) injection, a 2 mg dose of ABP 938, using the ABP 938 aflibercept prefilled syringe (PFS), compared to a 2 mg dose of aflibercept using the aflibercept PFS.

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT05986786` - Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease	Phase 3
	Completed	`NCT03767738` - Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe	Phase 4

See also

Status

Clinical Trial

Phase

Active, not recruiting

NCT05986786 - Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease

Phase 3

Completed

NCT03767738 - Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe

Phase 4

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05704725
Study type	Interventional
Source	Amgen
Contact
Status	Completed
Phase	Phase 3
Start date	January 23, 2023
Completion date	March 24, 2023

A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms